BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Talevi A. Drug repositioning: current approaches and their implications in the precision medicine era. Expert Review of Precision Medicine and Drug Development 2018;3:49-61. [DOI: 10.1080/23808993.2018.1424535] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Schuler J, Falls Z, Mangione W, Hudson ML, Bruggemann L, Samudrala R. Evaluating the performance of drug-repurposing technologies. Drug Discov Today 2022;27:49-64. [PMID: 34400352 DOI: 10.1016/j.drudis.2021.08.002] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A. DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Comput Biol Med 2019;109:254-62. [PMID: 31096089 DOI: 10.1016/j.compbiomed.2019.05.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
4 Shukla R, Henkel ND, Alganem K, Hamoud AR, Reigle J, Alnafisah RS, Eby HM, Imami AS, Creeden JF, Miruzzi SA, Meller J, Mccullumsmith RE. Signature-based approaches for informed drug repurposing: targeting CNS disorders. Neuropsychopharmacology 2021;46:116-30. [PMID: 32604402 DOI: 10.1038/s41386-020-0752-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Belllera CL, Sbaraglini ML, Alberca LN, Alice JI, Talevi A. In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach. In Silico Drug Design. Elsevier; 2019. pp. 625-48. [DOI: 10.1016/b978-0-12-816125-8.00021-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Orecchioni S, Roma S, Raimondi S, Gandini S, Bertolini F. Identifying Drug Repurposing Opportunities in Oncology. Cancer J 2019;25:82-7. [PMID: 30896529 DOI: 10.1097/PPO.0000000000000360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 2020;15:397-401. [PMID: 31847616 DOI: 10.1080/17460441.2020.1704729] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 17.3] [Reference Citation Analysis]
8 Natfji AA, Nikitin DO, Semina II, Moustafine RI, Khutoryanskiy VV, Lin H, Stephens GJ, Watson KA, Osborn HM, Greco F. Conjugation of haloperidol to PEG allows peripheral localisation of haloperidol and eliminates CNS extrapyramidal effects. Journal of Controlled Release 2020;322:227-35. [DOI: 10.1016/j.jconrel.2020.02.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]